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Abstract
Background: Intrauterine Growth Restriction (IUGR) due to placental insufficiency occurs in 5–10% of pregnancies and is a
major risk factor for abnormal neurodevelopment. The perinatal diagnosis of IUGR related abnormal neurodevelopment
represents a major challenge in fetal medicine. The development of clinical biomarkers is considered a promising approach,
but requires the identification of biochemical/molecular alterations by IUGR in the fetal brain. This targeted metabolomics
study in a rabbit IUGR model aimed to obtain mechanistic insight into the effects of IUGR on the fetal brain and identify
metabolite candidates for biomarker development.
Methodology/Principal Findings: At gestation day 25, IUGR was induced in two New Zealand rabbits by 40–50%
uteroplacental vessel ligation in one horn and the contralateral horn was used as control. At day 30, fetuses were delivered
by Cesarian section, weighed and brains collected for metabolomics analysis. Results showed that IUGR fetuses had a
significantly lower birth and brain weight compared to controls. Metabolomics analysis using liquid chromatography-
quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) and database matching identified 78 metabolites. Comparison
of metabolite intensities using a t-test demonstrated that 18 metabolites were significantly different between control and
IUGR brain tissue, including neurotransmitters/peptides, amino acids, fatty acids, energy metabolism intermediates and
oxidative stress metabolites. Principle component and hierarchical cluster analysis showed cluster formations that clearly
separated control from IUGR brain tissue samples, revealing the potential to develop predictive biomarkers. Moreover birth
weight and metabolite intensity correlations indicated that the extent of alterations was dependent on the severity of IUGR.
Conclusions: IUGR leads to metabolic alterations in the fetal rabbit brain, involving neuronal viability, energy metabolism,
amino acid levels, fatty acid profiles and oxidative stress mechanisms. Overall findings identified aspargine, ornithine, N-
acetylaspartylglutamic acid, N-acetylaspartate and palmitoleic acid as potential metabolite candidates to develop clinical
biomarkers for the perinatal diagnosis of IUGR related abnormal neurodevelopment.
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Introduction
Intrauterine Growth Restriction (IUGR) due to placental
insufficiency occurs in 5–10% of gestations and is a major
determinant of perinatal morbidity and mortality [1]. The
compromised placental blood supply results in sustained hypox-
emia and under-nutrition of the developing fetus [2], which can
affect fetal programming of vital organs and an increased risk for
disease later in life [3,4]. The fetal brain was shown to be
particularly vulnerable to prolonged IUGR conditions [5–6].
Clinical imaging studies demonstrated structural changes in the
brain of IUGR infants including altered white and grey matter
volumes [7–8], decreased levels of brain connectivity [9] and
delayed cortical development [10]. Moreover, several clinical
studies in neonates and infants who suffered IUGR showed both
short and long-term neurodevelopmental delays and cognitive
dysfunctions [11–12].
The early perinatal diagnosis of IUGR related abnormal
neurodevelopment represents a major challenge in fetal medicine.
At present abnormal neurodevelopment is primarily diagnosed
later in the child’s life and persists until late childhood and
adolescence [13–14]. The ability to diagnose abnormal neurode-
velopment during perinatal life would allow interventions during
the critical window of opportunity of the first two years of life,
when brain reorganization is particularly active and interventions
have shown to be effective in reverting the effects of adverse fetal
conditions [15]. The development of clinical biomarkers is
considered a promising approach to predict and monitor
abnormal neurodevelopment during perinatal life. Because the
effects of IUGR on the fetal brain are subtle, the approach will
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likely involve the identification of sensitive biochemical and/or
molecular imaging biomarkers [16]. The discovery and develop-
ment of such biomarkers requires an improved understanding of
the underlying molecular and biochemical mechanisms of IUGR
related abnormal neurodevelopment.
Metabolomics is defined as the quantitative measurement of the
dynamic metabolic response of living systems to genetic, physical,
pathological or developmental factors [17]. The technology has
emerged in numerous fields of research, including fetal medicine
aiming to facilitate the understanding of fetal disease pathophys-
iology and discovery of predictive biomarkers [18]. Previous
metabolomics studies have shown metabolic alterations in clinical
samples including cord blood and urine samples of IUGR
neonates [19–20]. Moreover, metabolic profiling studies in animal
IUGR models (e.g. rat and pig) pointed out alterations in blood
plasma, serum and jejunum metabolome as potential biomarkers
for the diagnosis of IUGR and its effects on fetal programming
[21–23]. To the best of our knowledge, the effects of IUGR on the
fetal brain metabolome have not yet been characterized.
The aim of this targeted metabolomics study was to obtain more
mechanistic insight into the effects of IUGR on the fetal brain and
identify potential metabolite candidates for the development of
clinical biomarkers for IUGR related abnormal neurodevelop-
ment. The study was undertaken in a rabbit model of IUGR,
which mimics placental insufficiency by the selective 40–50%
ligature of uteroplacental vessels [24]. Despite general species
differences, brain development in the rabbit is similar to that of
humans, but within a more compressed time-frame [25]. As in
humans, the temporal pattern of oligodendrocyte maturation,
myelination and functional changes occur most rapidly during the
perinatal period, starting several days before birth and continuing
during the postnatal period. Therefore the rabbit provides a
relevant and useful model to study perinatal processes of brain
development. Previous studies in the rabbit IUGR model, showed
that IUGR leads to impairment, hemodynamic adaptation,
alterations in white and grey brain matter and neurobehavioral
changes, as observed in IUGR infants [24,26]. The findings of this
targeted metabolomics study provide additional mechanistic
insights into the effects of IUGR on the fetal brain and support
the development of clinical biomarkers for the perinatal diagnosis
or treatment of IUGR related abnormal neurodevelopment.
Materials and Methods
The Rabbit IUGR Model
All animal procedures in this study were approved by the
Animal Experimental Ethics Committee of the University of
Barcelona. Moreover animal handling and procedures were
performed according the applicable regulations and guidelines of
the Animal Experimental Ethics Committee of the University of
Barcelona (Permit number: 2012/7684). The New Zealand
pregnant rabbits were provided by a certified breeder and dams
were housed for 1 week before surgery in separate cages on a
reversed 12/12 hour light cycle, with free access to water and
standard chow. IUGR was induced in two New Zealand pregnant
rabbits at 25 days of gestation by uteroplacental vessels ligation as
described in [24]. Briefly, after tocolysis and antibiotic prophylaxis
administration, an abdominal midline laparotomy was performed
under anaesthetic condition. Gestational sacs of both horns were
identified and, in one uterine horn, 40–50% of the uteroplacental
vessels of all gestational sacs were ligated, the contra lateral horn
was used as control. After the procedure the abdomen was closed
in two layers with a single suture of silk (3/0). Postoperative
analgesia was administered and animals were again housed with
free access to water and standard chow for 5 days until delivery
and well-being was controlled each day. Cesarean section was
performed at 30 days of gestation (term at 31 days) and nine living
(five control and four IUGR) and seven stillborn (one control and
six IUGR) fetuses were collected. After delivery, all living
newborns were weighed and sacrificed by immediate decapitation.
The fetal brains were removed, weighed and anterior hemisphere,
posterior hemisphere, basal ganglia and brain stem regions were
dissected on ice. The dissected brain tissues were snap frozen in
liquid nitrogen and thereafter stored at 280uC for subsequent
metabolomics analysis.
Sample Preparation Procedures
The frozen brain tissue regions were weighted and transferred
to an Eppendorf tube. For metabolite extraction (25 mL/mg of
tissue) ice cold high purity Methanol/Water mixture v/v 70/30
(Sigma Aldrich, Spain) was added. The brain tissues were
disrupted (on ice) using an ultrasound sonicator (Qsonica, CT,
USA) for 3–4 minutes until no more cellular debris was visible
in the tissue homogenate. To control for potential differences in
tissue quantities the total protein content of the homogenates
was quantified using a protein assay (BioRad). A standard
volume of 250 mL containing 10 mg of tissue was transferred to
a new Eppendorf tube, stored for 1 hour at 220uC and
centrifuged at 16,000 rcf, 4uC for 10 min. Supernatants were
collected, transferred to a new eppendorf tube and evaporated
to dryness at room temperature in a speedvac concentrator
(Thermo Scientific). The dried samples were reconstituted in
60 mL of 60% MeOH with 0.1% FA and clarified by
centrifugation at 14,000 rcf, 4uC for 5 minutes. The clarified
samples were transferred to plastic HPLC vials for LC-QTOF-
MS measurements.
Liquid Chromatography-quadrupole Time-of-flight Mass
Spectrometry Measurements
The LC-QTOF-MS measurements were performed using an
Agilent 1260 series LC binary pump and wellplate autosampler
coupled to a 6520 accurate-mass Q-TOF LC-MS system
equipped with a dual electrospray (ESI) ion source operated
in negative-ion mode (Agilent Technologies, Santa Clara, CA).
A Cogent Diamond Hydride TM (MicroSol, Eatontown, NJ)
aqueous normal phase (ANP) column (15062.1 mm i.d., 4 mm
particle size, 100 mm pore size) was used for separation of
metabolites. The LC parameters were as follows: autosampler
temperature, 4uC; injection volume, 5 ml; column temperature,
35uC; flow rate, 0.4 ml/min. The solvents and optimized
gradient conditions for LC were: Solvent A, 50% methanol/
50% water/0.05% formic acid; Solvent B, 90% acetonitrile with
5 mM ammonium acetate; elution gradient: 0 min–100% B;
20–25 min –40% B; post-run time for equilibration, 10 min in
100% B. A blank injection was run after every 3 samples. The
optimized ESI Q-TOF parameters for MS experiments were:
ion polarity, negative; gas temperature, 325uC; drying gas, 10 l/
min; nebulizer pressure, 45 psig; capillary voltage, 4,000 V;
fragmentor, 140 V; skimmer, 65 V; mass range, 70–1,100 m/z;
acquisition rate, 1.5 spectra/s; instrument state, extended
dynamic range (1,700 m/z, 2 GHz); Spectra were internally
mass calibrated in real time by continuous infusion of a
reference mass solution using an isocratic pump connected to a
dual sprayer feeding into an electrospray ionization source. Data
were acquired with MassHunter Acquisition software (Agilent
Technologies, Santa Clara, CA).
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Data Processing and Metabolite Identification
Following LC-QTOF-MS data acquisition, the acquired raw
data files were processed with Agilent MassHunter Qualitative
Analysis software (version 5.0). Reproducibility of chromatograms
was first inspected by overlaying the Total Ion Chromatograms
(TICs) of all samples. Data files that showed extraneous peaks were
excluded for further processing. To normalize the samples for
differences in tissue quantities the OD values of the protein assay
were integrated into the ion intensity quantification procedure.
The normalization procedure was confirmed by a comparison of
the total ion intensity of peaks in MS profiles. Initial, putative
metabolite identification was achieved by searching the accurate
m/z values of the peaks against an in-house built database derived
from HMDB, KEGG, METLIN and other public databases. At
the same time, the Extracted Ion Chromatograms (EICs) for these
matched putative metabolites were generated by performing Find
by Formula function integrated into the software. The abundance of
the EICs was calculated by summing the intensities of all
compound-related peaks (e.g. isotopic peaks, adduct peaks, etc.).
The pre-processed data files were imported into Agilent Mass
Profiler Professional software (version 12.1) for further statistical
analysis. MS/MS spectra and retention times acquired from
reference metabolites were used for confirmation of the identifi-
cation of statistically significant metabolites. More specifically, the
exact m/z values and intensities of fragment ions from the
acquired MS/MS spectra of putative metabolites must have a
reasonable match with that of reference metabolites or the
fragment ions from public databases (e.g. METLIN, MassBank),
if available.
Statistical Data Analysis
To identify statistical significant differences between the control
and IUGR fetal brain tissue samples the processed data files were
imported into Agilent Mass Profiler Professional software version
12.1 (Agilent Technologies, Santa Clara, CA) for statistical
analysis. The intensities of the 78 identified metabolites in control
and IUGR brain tissue samples were compared using a t-test (cut-
off p,0.05) followed by a Benjamini-Hochberg Multiple Testing
Correction. To visualize the variation within the dataset and most
contributing variables (metabolites), the significant metabolites
were used to perform a Principal Component Analysis (PCA) using
the first three components for data classification. A hierarchical
cluster analysis was used to demonstrate if control and IUGR fetal
brain tissue samples could be distinguished based on the profile of
the significantly altered metabolites. Correlations between fetal
birth weight and metabolite intensities were performed in
Graphpad Prism version 5 (GraphPad software, San Diego, CA).
Results
Fetal Birth and Brain Weight of Control and IUGR Rabbit
Fetuses
In total nine living (five control and four IUGR) and seven
stillborn (one control and six IUGR) fetuses were collected. The
mortality rate (60%) in the group of IUGR fetuses is inherent to
the induced IUGR conditions and in accordance with previous
studies [24]. The fetal birth and brain weight of the IUGR rabbit
fetuses was significantly lower compared to the control fetuses
(Table 1). The average birth weight for control fetuses (n = 5) was
52.7360.53 g and for IUGR (n = 4) 33.8667.17 g. The average
brain weight was 1.3260.05 g for control and 1.0760.13 g for
IUGR fetuses. One of the selected IUGR fetuses (I) had a
relatively high birth weight of 44.54 grams, which suggests it
developed under less severe IUGR conditions compared to the
other three IUGR fetuses.
Metabolic Differences between Control and IUGR Fetal
Brain Tissue
The matching of m/z values and extracted ion chromatograms
against the metabolite database and subsequent manual check for
matching scores and peak shapes resulted in the identification of
78 metabolites. To investigate if IUGR leads to metabolic
differences in the fetal rabbit brain, the ion intensities of the 78
metabolites in the control and IUGR fetal brain tissue samples
were compared using a t-test. Results showed that 18 of the 78
metabolites were significantly different (p,0.05). The statistically
significant metabolites, their p-values and description are shown in
Table 2. To visualize the metabolic differences, the mean
metabolite intensities in the control and IUGR fetal brain tissue
samples were plotted in graphs (Fig. 1A–D). The graphs showed
that most metabolites were significantly decreased in the IUGR
fetal brain tissue samples, including the brain metabolites; N-
acetylaspartylglutamic acid (NAAG), N-acetylaspartate (NAA) and
pyroglutamic acid, (Fig. 1A), the amino acids; ornithine, L-lysine,
aspargine, histidine and leucine intermediate 2-keto-isovalerate,
(Fig. 1B), the energy metabolism intermediates; succinate and
panthothenate, oxidative stress metabolites malondialdehyde and
3-nitrotyrosine, the nitrogen containing heterocycle purine and
organic acid 3,4-dihydroxybutyric acid (Fig. 1C). Metabolites that
were significantly increased included the nucleotide GMP and
Table 1. The birth and brain weight of the collected control and IUGR rabbit fetuses.
Control IUGR
Fetus Birth weight (g) Brain weight (g) Fetus Birth weight (g) Brain weight (g)
A 52.57 1.33 F 29.22 0.92
B 52.63 1.36 G 31.22 1.14
C 52.53 1.35 H 30.46 1.01
D 53.63 1.25 I 44.54 1.19
E 52.27 1.32
n 6 SD 52.7360.52 1.3260.05 n 6 SD 33.8667.17 (***) 1.0760.13 (**)
Data are presented as mean with standard deviation.
**denotes a statistically significant difference with p,0.01, and *** with p,0.001.
doi:10.1371/journal.pone.0064545.t001
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unsaturated fatty acids; docosahexaenoic acid (DHA), palmitoleic
acid and oleic acid (Fig. 1D).
Principal Component and Hierarchical Cluster Analysis
To study the statistically significant metabolic alterations in the
fetal brain due to the induction of IUGR more in depth, both a
principal component and hierarchical cluster analysis were
performed based on the ion intensities of the 18 significant
metabolites in the control and IUGR fetal brain tissue samples.
The results of the PCA (Fig. 2) showed that the control (in blue)
and IUGR (in red) fetal brain samples were clearly separated in
two groups along the first three principal components of the score
plot. The corresponding X-loading values (Table 3) revealed that
the metabolites, aspargine, NAA, pyroglutamic acid (positive
correlation) and palmitoleic acid (negative correlation) largely
contributed to the cluster formation along the first principal
component. The resulting heat map and dendrogram of the
hierarchical cluster analysis (Fig. 3) also showed two main clusters
that separated the control and IUGR fetal brain tissue samples. In
addition both clusters were subdivided in smaller clusters, which
largely reflected the different brain regions analyzed, creating
groups of hemisphere, basal ganglia and brain stem tissue samples.
Therefore the obtained results indicated that each brain region
comprises a characteristic metabolite profile and that the induction
of IUGR caused metabolic alterations in all brain regions. In
general the PCA and hierarchical cluster analysis revealed the
potential to distinguish between the normal and IUGR fetal brain
based on the comprehensive measurement of its metabolic profile
or status.
Correlations between Fetal Birth Weight and Metabolite
Intensity Alterations
In the clinical setting, estimated fetal birth weight is used as a
predictor for the severity of IUGR conditions. To investigate a
potential relationship between fetal birth weight and metabolic
alterations in the fetal brain of a rabbit IUGR model, the birth
weight of the control and IUGR fetuses was correlated with the
intensities of the 18 significantly altered metabolites. As expected,
the results showed a negative relationship for the decreased
metabolites and positive relationship for the metabolites that were
Figure 1. Metabolic differences between control and IUGR fetal brain tissue. Bar charts show the measured metabolite ion intensities of
NAAG, NAA, pyroglutamic acid (A), ornithine, L-lysine, aspargine, histidine and 2-keto-isovalerate (B), succinate, panthothenate, malondialdehyde, 3-
nitrotyrosine, purine and 3,4-Dihydroxybutyric acid (C), GMP, DHA, palmitoleic acid and oleic acid (D) in control (white bars) and IUGR (black bars)
fetal brain tissue. All metabolite ion intensities were significantly different (p,0.05) based on a t-test followed by a Benjamini-Hochberg Multiple
Testing Correction. Data are presented as mean, control (n = 5) and IUGR (n = 4) fetal brains with error bars representing standard deviation.
doi:10.1371/journal.pone.0064545.g001
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increased in the fetal IUGR brain. The highest correlation
coefficients between birth weight and metabolite intensities were
observed for the metabolites aspargine (r2 = 0.6723), (Fig. 4A),
ornithine (r2 = 0.5422) (Fig. 4B), palmitoleic acid (r2 = 0.4938),
(Fig. 4C) and NAAG (r2 = 0.3712) (Fig. 4D). The correlations also
revealed that the brain tissue samples obtained from the IUGR
fetus with the highest birth weight (fetus I; 44.45 g) included
metabolite ion intensities more similar to the controls (Fig. 4A–D).
This suggests that the observed alterations in metabolite ion
intensities were dependent on the severity of the IUGR conditions,
as reflected by fetal birth weight.
Discussion
The present study applied a targeted metabolomics approach in
a rabbit IUGR model to obtain improved insight into the effects of
IUGR on the developing fetal brain and identify potential
metabolite candidates to develop perinatal biomarkers for IUGR
related abnormal neurodevelopment. Results showed that the
induction of IUGR by 40–50% uteroplacental vessels ligation in
the pregnant rabbit caused a significant decrease in the fetal birth
and brain weight of the rabbit fetuses. These findings correspond
with clinical observations in IUGR neonates, who besides a low
birth weight were shown to have a decreased brain volume [27].
Therefore this study provides further supporting evidence that the
rabbit IUGR model used is able to reproduce physiological
features of the human IUGR condition and therefore could
provide clinically relevant information regarding the effects of
IUGR on fetal brain. Targeted metabolic profiling in the rabbit
IUGR model showed that IUGR leads to statistically significant
metabolic alterations in the fetal rabbit brain. The metabolic
differences included ion intensity alterations in neurotransmitters/
peptides, amino acids, fatty acids, energy metabolism intermedi-
ates and oxidative stress related metabolites. The identified
alterations in brain metabolites could be useful to support the
development of clinical biomarkers for the early perinatal
diagnosis of IUGR related abnormal neurodevelopment and the
discovery of potential therapeutic targets for fetal therapy.
Previous studies in animal model of the IUGR condition have
shown that IUGR adversely affects brain development and
organization [5–6]. The results obtained in this study showed a
statistically significant decrease in the brain specific metabolites
NAAG and NAA in the brain tissue of IUGR fetuses compared to
control fetuses. NAAG and NAA are primarily present in neurons
and oligodendrocytes and are well known markers for neuronal
density and viability [28]. Moreover, NAA is synthesized in
neuronal mitochondria and is therefore considered a marker for
neuronal mitochondrial metabolism [29]. The observed decrease
in NAAG and NAA metabolites therefore indicate that IUGR has
a direct adverse effect on neurons and oligodendrocytes by
perturbing neuronal viability, energy metabolism and the myeli-
nation process. These results are in agreement with previous brain
histology studies in animal IUGR models, which demonstrated
that IUGR adversely affected the myelination process [30] and
caused the induction of neuronal cell death [6,31]. Moreover, a
previous MRI study in the identical rabbit IUGR model observed
a decrease in white matter myelination [26]. A potential adverse
effect of IUGR on neuronal energy metabolism was supported by
the identified decrease in the energy metabolism intermediates
succinate and pantothetic acid. Decreased succinate levels have
been previously proposed as an indicative marker for disrupted
neuronal energy metabolism in an Alzheimer’s disease mice model
[32]. A study of brain metabolism in normal and IUGR fetuses
using proton magnetic resonance spectroscopy also showed
decreased NAA levels in the fetal IUGR brain [33]. Therefore
the identified decrease in NAAG and NAA metabolites in the
rabbit IUGR model further support previous findings that IUGR
alters neuronal metabolism in the fetal brain.
Table 2. Metabolites with significantly different ion intensities in control and IUGR fetal brain tissue.
Metabolite P value Mass Description
Asparagine 0,0000242 132,0534 Amino acid
Ornithine 0,0000275 132,0894 Amino acid
Palmitoleic acid 0,0000372 254,2249 Monounsaturated fatty acid
3-Nitrotyrosine 0,000543 226,0599 Marker of protein nitration
N-Acetylaspartylglutamic acid (NAAG) 0,000632 304,0914 Neurotransmitter
2-keto-isovalerate 0,001535 116,0474 Leucine biosynthesis intermediate
GMP 0,001535 363,0578 Nucleotide
Histidine 0,002027 155,0695 Amino acid
Docosahexaenoic acid (DHA) 0,002243 328,2408 Polyunsaturated fatty acid
N-acetylaspartate (NAA) 0,002243 175,0482 Neuropeptide
Purine 0,002375 120,0426 Nitrogen containing heterocycle
Oleic acid 0,003172 282,2564 Monounsaturated fatty acid
L- Lysine 0,003892 146,1056 Amino acid
Pyroglutamic acid 0,003892 129,0428 Precursor of glutamate
Pantothenate 0,003892 219,1108 Precursor of coenzyme A
Malondialdehyde 0,004639 72,02118 Lipid peroxidation marker
Succinate 0,005183 118,0267 Citric acid cycle intermediate
3,4-Dihydroxybutyric acid 0,029617 120,0425 Organic acid
According to a t-test followed by a Benjamini-Hochberg Multiple Testing Correction.
doi:10.1371/journal.pone.0064545.t002
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Besides neurospecific metabolites, results showed a statistically
significant decrease in the ion intensities of several amino acids in
the fetal IUGR brain, including aspargine, histidine, ornithine, L-
Lysine. Previous studies in animal models have already demon-
strated that IUGR due to placental insufficiency causes a reduced
placental transport of amino acids to the fetal blood circulation
[33–35]. In addition, measurements of amino acids concentrations
in maternal and fetal blood plasma of normal and IUGR
pregnancies showed a significant reduction in amino acid levels
in the blood plasma of IUGR fetuses [36]. The results obtained in
this study suggest that IUGR can lead to reduced amino acid levels
in the fetal brain of a rabbit model. Because amino acids are
important for brain growth, metabolism and function, a potential
reduction in the fetal brain could have a role in IUGR related
abnormal neurodevelopment such as changes in brain volumes
[27,37], connectivity patterns [9] and cognitive dysfunctions [11–
12].
Metabolites found to be statistically significant increased in the
IUGR fetal rabbit brain included the monounsaturated fatty acids
palmitoleic acid, oleic acid and polyunsaturated fatty acid DHA.
Both types of fatty acids are essential parts of brain cell membranes
and myelin sheets and play a crucial role in neurodevelopment
[38–40]. From animal and clinical studies it is known that fatty
acids accumulate during pregnancy in the adipose tissue and brain
of the developing fetus [41–42]. There have been few studies on
brain fatty acid profiles in animal models of IUGR, one reported
study in a rat IUGR model found no significant differences in fatty
acid composition between the control and IUGR fetal brain [43].
In clinical studies however, it was shown that IUGR fetuses have
higher levels of free fatty acids and triglycerides in blood plasma
compared to normal fetuses, related to changes in lipid metabo-
Figure 2. Principal Component Analysis (PCA) score plot showed a clear cluster separation of the control (blue) and IUGR (red) fetal
brain tissue samples. The PCA was based on the significant metabolites identified by the t-test. The plot shows the first three principal
components that include PC1:49.83%, PC2:12.77% and PC3:9.23% percentage of total variables.
doi:10.1371/journal.pone.0064545.g002
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lism and distribution [44]. Further studies on fetal brain lipid
compositions in normal and IUGR pregnancies should clarify if
the increased lipid levels detected in the rabbit model are clinically
relevant.
Metabolic profiling also showed alterations in oxidative stress
related metabolites including the lipid peroxidation marker
malondialdehyde [45] and protein nitration marker 3-nitrotyr-
osine [46]. Although IUGR has been mostly shown to induce an
oxidative stress response, both markers were found to be decreased
in the fetal IUGR brain tissue. Since the redox status of a
biological system changes rapidly, the levels of oxidative stress
metabolites depend largely on the time point of measurement. It is
likely that the release of hypoxic-ischemic conditions after delivery
by cesarean section changed the dynamic oxidative stress related
metabolism in the fetal brain. Therefore, it is difficult to interpret
the measured alterations in the oxidative stress markers and draw
any conclusions. Nevertheless the fact that both oxidative stress
markers were among the significantly altered metabolites suggest
that oxidative stress plays a role in the fetal brain under IUGR
conditions. An improved study design allowing the in vivo
measurement of oxidative markers in the fetal brain of the rabbit
IUGR model would be required to obtain a detailed understand-
ing of the oxidative stress response in the IUGR fetal brain.
Multivariate data analysis by PCA and hierarchical cluster
analysis demonstrated that control and IUGR fetal brain tissue
samples (from the identical pregnant rabbit) could be clearly
distinguished based on their metabolite profiles. The PCA loadings
indicated that the neuropeptide (NAA) amino acid (aspargine,
ornithine) and fatty acid (palmitoleic acid) primarily contributed to
the separation along the first principal component, which included
most of the total variance in the dataset. These contributions make
these metabolites interesting candidates for the development of
clinical biomarkers using non-invasive clinical imaging techniques
in the fetal brain. Even though the PCA results showed that IUGR
had a global effect on the fetal rabbit brain by separating control
and IUGR brain tissue samples from all studied brain regions, the
metabolic differences were found to be predominant in the
hemisphere brain regions. This suggests that the frontal brain
regions are primarily susceptible for IUGR conditions, as was
earlier suggested by clinical imaging [47] and behavioral studies
[48].
Figure 3. Dendrogram and heatmap showing the metabolic differences between control and IUGR fetal brain tissue samples. The
significantly altered metabolites were hierarchically clustered (columns) and ratios plotted on a color scale (rows). The dendrogram showed a clear
cluster formation between the control (blue) and IUGR (red) samples. In addition, smaller clusters are visible, which mostly group the hemisphere
anterior (HA), hemisphere posterior (HP) basal ganglia (BG) and brain stem (BS) regions.
doi:10.1371/journal.pone.0064545.g003
Table 3. The X-loading values for the first principal
component of the PCA score plot.



















X-loading values show positive and negative correlations responsible for the
cluster formation along the first principal component (PC1) in the PCA score
plot.
doi:10.1371/journal.pone.0064545.t003
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Strengths and Limitations
The main strength of this study includes the unique combina-
tion of a rabbit IUGR model and metabolomics approach. The
rabbit IUGR model was previously shown to mimic the human
IUGR condition. Furthermore it enables a direct comparison of
control and IUGR fetuses from the same mother. This study
design reduces variability factors and avoids the requirements of
large study groups of animals. Metabolomics can provide
information on phenotypic outcomes of disease processes (IUGR
conditions), which are highly relevant for biomarker candidate
identifications. The sensitivity of the LC-QTOF-MS metabolo-
mics technology allowed the detection of metabolite alterations
related to subtle effects of IUGR conditions on the fetal brain.
Limitations include the quantification of metabolites in brain tissue
extracts instead of the tissue itself, therefore the measured
metabolite levels might not correspond with in vivo concentrations.
To overcome this limitation the in vivo metabolite levels should be
determined by non-invasive techniques such as NMR or MRI
spectroscopy. Nevertheless these techniques do not have the
sensitivity of the applied LC-QTOF-MS approach. As expected
not all measured metabolites could be identified using the current
up-to-date metabolite databases. Therefore there could be
additional metabolite candidates suitable for clinical biomarker
development. The raw data of this study will be stored and as
metabolite databases will expand there will be opportunities for
additional metabolite identifications. Finally this study was only
able to provide a snapshot view of the dynamic metabolic
processes in the fetal IUGR brain. To have a more comprehensive
understanding of the progressive adverse effects of IUGR on the
fetal brain, a larger scale time course metabolomics study would be
required. Such a comprehensive analysis was beyond the scope of
this initial study; however the results here obtained encourage the
performance of an extended metabolomic profiling study. Despite
these limitations the results of this study provide new mechanistic
insights and demonstrate the potential to develop a prediction
model for the effects of IUGR on the fetal brain based on tissue
metabolic profiles.
From a clinical perspective, this study provides preliminary
evidence supporting further research on the development of
metabolic biomarkers associated with growth restriction and its
neurodevelopmental correlates. Current challenges in fetal med-
icine include the correct classification of true growth restriction
from physiologic smallness, particularly among fetuses with
borderline estimated fetal weights. Such differentiation is critical
to establish early-life intervention measures to correct for the
impact of IUGR on neurodevelopment. Thus, it is imperative to
develop classification algorithms. Likewise, biomarkers will be a
critical need for the monitoring of the effectiveness of interventions
in the correction of neurodevelopmental deviations. The design of
such models will necessarily integrate clinical parameters, such as
Figure 4. Correlation graphs between fetal birth weight and metabolite ion intensities. The metabolites aspargine (r2 = 0.6723) (A),
ornithine (r2 = 0.5422) (B), palmitoleic acid (r2 = 0.4938) (C) and NAAG (r2 = 0.3712) (D) showed the highest correlation coefficient. Brain tissue samples
from IUGR fetus with the highest birth weight (I), showed metabolite intensities more similar to the controls. Each point represents a single fetal brain
tissue sample.
doi:10.1371/journal.pone.0064545.g004
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fetal birth weight and hemodynamic measures, together with more
sophisticated blood or imaging biomarkers. Brain metabolic
signatures could be determined by MRI spectroscopy and be
useful markers as part of predictive scores to facilitate the perinatal
diagnosis and monitoring of IUGR related abnormal neurodevel-
opment. Implementation of metabolomics technologies in clinical
practice will require translational studies to demonstrate the
feasibility of measuring metabolite candidates by means of non-
invasive clinical imaging techniques in animal models and
eventually patients.
In summary, this targeted metabolomics study demonstrates
that IUGR leads to statistically significant metabolic alterations in
the fetal rabbit brain, involving neuronal viability, energy
metabolism, amino acid levels, fatty acid profiles and oxidative
stress mechanisms. The identified metabolic alterations showed a
dependence on the severity of IUGR conditions (reflected by birth
weight) and allowed a clear discrimination between control and
IUGR fetal brain tissue, which revealed the potential to develop
biochemical biomarkers for the perinatal diagnosis of IUGR at its
related abnormal neurodevelopment. Overall results identified
aspargine, ornithine, NAAG, NAA and palmitoleic acid as the
most promising metabolite candidates for further biomarker
development studies based on non-invasive clinical imaging
techniques.
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